- 1 Title: Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for
- 2 Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults
- 3 in Germany
- 4 Authors: Caihua Liang<sup>1</sup>, Elizabeth Begier<sup>2</sup>, Stefan Hagel<sup>3</sup>, Juliane Ankert<sup>3</sup>, Liz Wang<sup>1</sup>,
- 5 Claudia Schwarz<sup>4</sup>, Lea J. Bayer<sup>5</sup>, Christof von Eiff<sup>5</sup>, Qing Liu<sup>4</sup>, Jo Southern<sup>4</sup>, Jeffrey Vietri<sup>4</sup>,
- 6 Sonal Uppal<sup>4</sup>, Bradford D. Gessner<sup>4</sup>, Christian Theilacker<sup>4</sup>, Mathias Pletz<sup>3</sup>
- 7 Affiliations:
- <sup>8</sup> <sup>1</sup>Pfizer Inc-New York (USA)
- 9 <sup>2</sup>Pfizer Inc-Dublin (Ireland)
- <sup>3</sup> Institute for Infectious Diseases and Infection Control and Center for Sepsis Care and Control
- 11 (CSCC), Jena University Hospital, Friedrich- Schiller-University, Jena, Germany
- 12 <sup>4</sup>Pfizer Inc-Collegeville (USA)
- 13 <sup>5</sup>Pfizer Pharma GmbH, Berlin (Germany)
- 14 **Correspondence Details:**
- 15 Mathias W. Pletz (<u>mathias.pletz@med.uni-jena.de</u>)

#### 16 **Abstract:**

17 Background: RSV is a leading cause of ARI, including CAP, in older adults, but available data 18 often substantially underestimate incidence. We estimated RSV-related ARI hospitalization 19 incidence from a prospective CAP study and adjusted for undiagnosed RSV infections due to 20 use of nasopharyngeal/nasal swab testing only. 21 Methods: We conducted active, population-based surveillance of adult CAP hospitalizations in 22 Thuringia (Germany) between 2021–2023. Participant nasopharyngeal/nasal swabs were RSV-23 tested by multiplex nucleic acid amplification testing. To estimate RSV-related CAP incidence. 24 age-group specific proportions of RSV positivity among tested patients were applied to all-cause 25 CAP incidence. To adjust for underdiagnosis due to nasopharyngeal/nasal swab sampling only 26 and the percentage of ARI with pneumonia diagnoses, we used data from a large, prospective, 27 multispecimen study assessing impact of collecting multiple specimens (nasopharyngeal/nasal 28 swab, saliva, paired serology, and sputum) among 3,669 adults hospitalized for ARI. 29 Results: Among 1,040 enrolled adults (≥18 years) with radiologically confirmed CAP, 38 tested 30 RSV-positive via nasopharyngeal/nasal swab (3.7%). The percentage positive increased to 31 7.8% after adjusting for higher RSV detection with multiple specimens compared to 32 nasopharyngeal/nasal swab only. Adjusted RSV-related CAP hospitalization rates were 4.7 33 (95%CI 1.5–11.2) and 109.1 (95%CI 89.6–131.6) per 100,000 adults aged 18–59 and ≥60 34 years, respectively. Adjusted incidences of RSV-related ARI were 18.4 (95%CI 11.0-28.9) and 35 377.6 (95%CI 340.5–417.7) per 100,000 adults aged 18–59 and ≥60 years, respectively. 36 Among RSV-positive CAP hospitalizations, 12.1% of patients aged ≥65 years died within 30 37 days, with no deaths in those aged 18-64 years. Cardiovascular events occurred in 11.1% of 38 patients aged 18–64 and 36.4% of those aged  $\geq$ 65 years. 39 **Conclusions:** Older adults in Germany face a high burden of RSV-related ARI hospitalizations,

40 including CAP, underscoring RSV vaccination's potential utility for this population.

41

- 42 **Key words:** Community-acquired pneumonia; Respiratory syncytial virus; Acute respiratory
- 43 infection hospitalization
- 44

## 45 **Conflicts of interests**

- 46 This study was funded by Pfizer Inc. Caihua Liang, Elizabeth Begier, Liz Wang, Claudia
- 47 Schwarz, Lea J. Bayer, Christof von Eiff, Qing Liu, Jo Southern, Jeffrey Vietri, Sonal Uppal,
- 48 Bradford D. Gessner, Christian Theilacker are Pfizer employees and may own Pfizer stock.
- 49 Stefan Hagel and Mathias Pletz received speaker honoraria and research funding from Pfizer.
- 50

## 51 **Funding**

52 This study was funded by Pfizer Inc.

## 53 **KEY PUBLIC HEALTH MESSAGE**

### 54 What did you want to address in this study and why?

55 Hospital administrative data significantly underestimate respiratory syncytial virus (RSV) 56 incidence due to infrequent testing and lower sensitivity of single nasopharyngeal/nasal swab 57 testing among adults. No prospective incidence studies are available for Germany and most 58 other European countries. We aimed to estimate RSV-related acute respiratory infection (ARI) 59 hospitalization incidence from a prospective community-acquired pneumonia (CAP) study and 60 adjust for undiagnosed RSV infections due to limited testing and use of nasopharyngeal/nasal 61 swab testing only. Detailed data on RSV disease burden are crucial for developing vaccination 62 policies.

## 63 What have we learnt from this study?

64 Adjusted annual incidence of RSV-related ARI rates were 18.4 (95% CI 11.0–28.9) and 377.6

65 (95% CI 340.5–417.7) per 100,000 population for adults 18–59 and  $\geq$ 60 years, respectively.

66 Among RSV-positive CAP hospitalizations, 12.1% of patients aged ≥65 years died

67 within 30 days, with no deaths in those aged 18–64 years. Cardiovascular events

occurred in 11.1% of patients aged 18–64 and 36.4% of those aged  $\geq$ 65 years.

## 69 What are the implications of your findings for public health?

Our findings are similar to recent time-series incidence results from Germany (236–363/100,000
for adults ≥60 years) and underscore the substantial burden of RSV among adults, particularly
the high rate of cardiovascular events contributes to a probably underestimated burden of RSV
disease.

### 74 Introduction

75 Lower respiratory tract infections (LRTIs) are leading causes of morbidity and mortality globally 76 [1, 2]. Pneumonia is the most common diagnosis of hospitalized acute lower respiratory tract 77 disease (aLRTD), accounting for 31% of aLRTD in a UK study [3] and 29% in a US prospective 78 cohort study [4]. In Germany, a recent retrospective cohort study using a representative 79 healthcare claims database reported an incidence of hospitalized community-acquired 80 pneumonia (CAP) 1,061 per 100,000 person-years in adults aged ≥60 years [5]. 81 82 Respiratory syncytial virus (RSV) is now being recognized as one of the leading causes of acute 83 respiratory infections (ARIs) in older adults, including among patients with pneumonia [6, 7]. A 84 recent global systematic literature review and metanalysis reported a pooled adjusted RSV-85 related ARI hospitalization incidence of 347 per 100,000 for adults aged ≥65 years, 86 corresponding to 787,000 annual hospitalizations among older adults in high-income countries 87 [8]. In the US, roughly 2–9% of older adult pneumonia hospitalizations have been attributed to 88 RSV [6, 9] and this fraction increases to up to 15% during the winter months depending on the 89 diagnostic approaches used and the season under investigation [4, 10, 11]. RSV-related ARI 90 hospitalizations include pneumonia, but also non-pneumonic LRTI and exacerbations of 91 cardiopulmonary disease caused by RSV infection. In one study in Finland, pneumonia

92 accounted for 14% (3/22) of RSV-related ARI hospitalizations [4]. A more recent prospective

93 study using multiple specimen types found pneumonia to comprise 28% (71/254) of RSV-

94 related ARI hospitalizations when multiple additional specimen types (i.e., sputum, saliva and

95 blood) were added rather than relying on nasopharyngeal (NP)/nasal swab alone [12].

96

Accurate estimation of RSV-related hospitalization incidence is challenging due to several
 causes of RSV case underascertainment [13]. RSV clinical presentation is non-specific and thus
 diagnostic testing is necessary for confirmation of infection [10]; however this is infrequently

100 performed because it usually does not impact clinical management [13, 14]. When performed, 101 RSV laboratory testing may miss 50% of infections if only a single specimen is used for 102 diagnostic testing (often NP/nasal swab reverse transcription polymerase chain reaction [RT-103 PCR]) [15, 16]. This is likely due to viral titers in respiratory secretions in adults being typically 104 lower than titers in children, so that RSV may no longer be detectable at the time of testing at 105 presentation/hospital admission [17], which tends to occur later in illness than for other 106 respiratory viruses [13].

107

108 Current assessments of RSV burden focus on RSV-related ARI hospitalizations, conducted 109 either through prospective studies utilizing direct diagnostic testing, retrospective studies using 110 diagnosis codes from large administrative databases, or through time-series modeling 111 approaches. Due to the reduced sensitivity of a single RT-PCR NP/nasal swab, prospective 112 estimates should be adjusted by the percentage increase in RSV detections associated with 113 using multiple diagnostic specimen types [8, 18]. Estimates based on diagnosis/ICD codes only 114 have been shown to substantially underestimate the RSV incidence globally and in Germany 115 [18-20]. Model-based studies link the variations in a broad definition of respiratory disease (e.g. 116 all respiratory diseases) to the variation in RSV activity to estimate the proportion of respiratory 117 disease attributable to RSV. This non-specific outcome definition can account for the 118 undiagnosed RSV cases, which might have been coded as other diseases [20, 21]. However, 119 results can vary by different modeling approaches and viral activity proxies selected and 120 prospective incidence studies are considered the gold standard. 121 122

123 prospective testing are available for Germany. We used data from a prospective study of CAP 124

incidence [22] to estimate RSV-related CAP and ARI hospitalization incidence, including

Currently, no RSV-related hospitalization estimates based on active surveillance and

125 adjustment for undiagnosed RSV infections due to use of NP/nasal swab testing only and non-

- 126 CAP ARI events.
- 127

## 128 Methods

129 Study design and study population

130 The CAP incidence study is a population-based multi-hospital, prospective study to determine 131 the CAP hospitalization incidence rate among adults aged  $\geq$ 18 years in Thuringia, Germany. 132 Active surveillance for CAP has been conducted at three hospitals: Jena University Hospital 133 (JUH); the SRH Wald-Klinikum Gera; and the SRH Zentralklinikum Suhl. Study period for this 134 analysis is July 2021–June 2023 (24 months), encompassing two winter seasons. Adults who 135 met the following inclusion criteria were offered enrollment: aged ≥18 years at the time of 136 hospital admission with CAP and had evidence of pneumonia within first 48 hours of hospital 137 admission based on radiologic findings consistent with pneumonia and presence of  $\geq 2$  of 138 following 10 clinical signs or symptoms (fever within 24 hours before enrollment; hypothermia 139 within 24 hours of enrollment; chills or rigors; pleuritic chest pain; new or worsening cough; 140 sputum production; dyspnea; tachypnea; malaise; abnormal auscultatory findings suggestive of 141 pneumonia). Patients with radiologically-confirmed CAP were included in the analysis. The 142 number of unenrolled persons meeting inclusion/exclusion criteria was recorded to allow for 143 enumeration of all CAP hospitalizations regardless of enrollment status.

144

145 Data sources

NP/nasal swabs (or alternatively mid-turbinate nasal swabs) were collected from enrolled
 participants and tested by multiplex nuclear acid amplification test (NAAT) for the presence of
 respiratory viruses, including RSV.

The following data were collected from the study participants and hospital records on admission: age, gender, study period, smoking status, alcohol use and chronic medical conditions. The risk level was classified as low risk, at-risk and high-risk using CDC definitions for pneumococcal disease [23], which are similar to risk factors for severe RSV infection [24, 25]. Cardiovascular events were defined as any of the following: new or worsening heart failure, new or worsening arrhythmia, acute coronary syndrome, cerebrovascular accident, deep venous thrombosis or pulmonary embolism, or cardiovascular-related death.

156

#### 157 Definition of Catchment Area Population

To estimate the RSV-related CAP incidence, the catchment area population was defined based on residential zip codes. As uninterrupted CAP surveillance with full case capture was only available from JUH, incidence estimations are based on this study site only. The total population of adults aged ≥18 years from catchment area zip codes formed the denominator of the incidence calculation. The observed unadjusted incidence rates were multiplied by the inverse of the hospital market share in the catchment area (i.e., 97%) to adjust for healthcare seeking at other facilities by residents of the catchment area.

165

#### 166 Statistical analysis

167 Demographics and risk status were descriptively summarized for all patients meeting the case-

168 definition for CAP, according to testing status (tested and untested) and regardless of their

169 enrollment status. All variables were classified as either binary or categorical and are presented

170 as counts with percentages. The RSV positive proportion from NP/nasal swab alone

171 (unadjusted) was calculated as the number of RSV positive cases divided by the total number of

172 participants who had a valid NP/nasal swab test result. In order to adjust for underascertainment

173 of RSV detection based on use of NP/nasal swab testing alone, we used results from the

174 previously published prospective study detecting RSV using multispecimen types (referred to as 175 multispecimen study hereafter) [12]. The percent increase in RSV detection rate associated with 176 additional specimens was calculated using the positive proportion from NP/nasal swab plus 177 other specimens (i.e., saliva, paired serology, and sputum) and the positive proportion from 178 NP/nasal swab alone. This percent increase among different age groups served to correct for 179 underascertainment of RSV cases due to missed RSV infections associated with 180 nasopharyngeal/nasal swab diagnostic testing only.

181

182 The unadjusted RSV-related CAP incidence rates were calculated by multiplying age-group 183 specific proportions of RSV detection among tested patients with all-cause CAP incidence for all 184 eligible participants enrolled at Jena site, based on the assumption that RSV detection rate 185 would not differ significantly between those tested and untested. The adjusted RSV-related CAP 186 incidence rates were calculated using the percent increase in RSV detection obtained from the 187 multi-specimen study [12]. This was achieved by multiplying percent increase associated with 188 using multiple diagnostic testing specimens with the unadjusted RSV-related CAP incidence. 189 Incidence rate of RSV-related ARI hospitalizations (both unadjusted and adjusted) was then 190 estimated by dividing the RSV-related CAP incidence rates (unadjusted and adjusted) by the 191 proportions of CAP among RSV-associated ARI hospitalizations by age group, obtained from 192 the multi-specimen study [12]. The corresponding 95% confidence intervals (CIs) were 193 calculated by the exact method using Poisson distribution. R version 4.3.0 and SAS version 9.4 194 (SAS 9.4, Cary, NC. SAS Institute Inc.) were used to perform all analyses. 195

196 Ethics/Ethical Approval

All study participants or legal representatives were informed about the study and consented to
the participation. Local ethics committees approved the conduct of the study (2020-1947-

199 material).

200

#### 201 **Results**

At JUH, there were 293 patients hospitalized with CAP tested for RSV by NP/nasal swab and 741 were not tested (including enrolled and non-enrolled patients). Patients not tested were slightly older (84.2% aged  $\geq$ 65 years vs 77.5%), had lower prevalence of high-risk conditions (38.7% vs 58.4%) but a higher prevalence of at-risk conditions (52.8% vs 35.5%) than tested individuals (Table 1).

207

## 208 RSV detection among CAP patients

209 Among 1,040 radiologically confirmed CAP cases enrolled and tested at the three study sites 210 between 01 July 2021 and 30 June 2023, 38 CAP cases had RSV detected, with an overall 211 positive proportion of 3.7% among adults aged ≥18 years (Supplementary Table S1). RSV 212 positive proportions were higher in the older age group (4.1% vs 2.4% for adults aged  $\geq 60$  years 213 and 18-59 years, respectively) and were generally higher in Year 2 (01. July 2022-30. June 214 2023) (5.5%) than Year 1 (01. July 2021–30. June 2022) (2.3%), however, they were similar 215 across risk status (3.3% for low-risk, 3.5% for at-risk and 3.9% for high-risk). After adjustment 216 for underascertainment of RSV cases, the overall positive proportion increased from 3.7% to 217 7.8%, corresponding to a 112% increase in RSV detection resulting from adding multiple 218 specimen results (i.e., saliva, paired serology, and sputum) beyond NP/nasal swab (Table 2).

219

## 220 Incidence of RSV-related CAP and ARI hospitalization

The unadjusted RSV-related CAP hospitalization rates were 1.9 (95% Cl 0.2, 7.1) per 100,000 population in adults aged 18-59 years and 54.3 (95% Cl 40.8, 70.8) per 100,000 population in adults aged  $\geq$ 60 years, respectively. Using the age-group specific percent increase in detection associated with testing with additional specimen types (i.e., saliva, paired serology, and sputum) as compared to NP/nasal swab alone from the multispecimen study [12] (Supplemental Table

226	S2), the adjusted incidence rate of RSV-related CAP hospitalizations was 4.7 (95% CI 1.5, 11.2)
227	per 100,000 population for adults aged 18–59 years and 109.1 (95% CI 89.6, 131.6) per
228	100,000 population for those aged ≥60 years. After applying the proportions of CAP among the
229	RSV-related ARI hospitalizations across different age groups [12], the estimated incidence rates
230	of RSV-related ARI hospitalizations (adjusted) were 18.4 (95% CI 11.0, 28.9) per 100,000
231	population for adults aged 18-59 years, and 377.6 (95% CI 340.5, 417.7) per 100,000
232	population for adults aged ≥60 years (Table 2). Incidence estimates in Year 2 were about 3
233	times higher than in Year 1.
234	
235	RSV-related CAP hospitalization outcomes
236	Among RSV-positive CAP hospitalizations, 12.1% of patients aged ≥65 years died within 30
237	days of hospitalization; no deaths were observed for those aged 18–64 years among the 9
238	RSV-related CAP hospitalizations. Cardiovascular events (i.e., heart failure, arrhythmia, acute
239	coronary syndrome, cerebrovascular accident, deep venous thrombosis or pulmonary
240	embolism, and cardiovascular-related death) occurred in 11.1% and 36.4% of RSV-positive
241	patients 18–64 and $\geq$ 65 years of age within 30 days of CAP hospitalization.
242	
243	Discussion
244	This analysis estimated the incidence rate of RSV-related ARI hospitalizations among adults
245	between 2021 to 2023 using the RSV incidence derived from an active surveillance CAP study
246	in Thuringia, Germany. The RSV positive proportion from NP/nasal swabs alone was 3.7% and

247 increased to 7.8% when adjusted for undiagnosed infections due to use of a single NP/nasal

swab compared to sampling with multiple diagnostic specimens (i.e., saliva, sputum, paired

249 acute/convalescent serology, and NP/nasal swab). With further adjustment for RSV-related

250 clinical presentations beyond CAP (e.g., non-pneumonic LRTI as well as chronic obstructive

251 pulmonary disease [COPD] and congestive heart failure [CHF] exacerbations), the adjusted

incidence rates of RSV-related ARI hospitalization for persons aged 18–59 years and ≥60 years
were 18 and 378 per 100,000 population, respectively. Finally, RSV-related CAP was
associated with a high risk for cardiovascular events within the month following CAP onset.

256 Results of our study are closely comparable to other RSV-related ARI hospitalization incidence 257 rates in the literature. First, these values were similar to a recent time-series model-based study 258 in Germany [21] (19-30, 33-51 and 236-363 cases per 100,000 person-years in adults aged 259 18-44, 45-59 and  $\geq$ 60 years, respectively). Our estimates also aligned with incidence rates 260 reported in two systematic literature reviews with meta-analyses that included adjustment for 261 undiagnosed infections due to sole use of NP/nasal swab testing: one global meta-analysis of 262 prospective studies in high-income countries [8] (70 and 347 cases per 100,000 population in 263 adults aged 18-64 years and ≥65 years, respectively), and a US meta-analysis (19, 100, and 264 282 cases per 100,000 population in adults aged 18-49, 50–64, and  $\geq$ 65 years, respectively) 265 [18].

266

267 We adjusted for undiagnosed RSV infections due to RSV detection relying on single NP/nasal 268 swab testing. Most RSV disease incidence studies in adults solely use RT-PCR of a NP/nasal 269 swab for RSV detection [8, 18], but multiple studies document that single specimen testing 270 misses RSV infections, and that adding an additional specimen such as sputum and paired 271 serology increases detection approximately 50% [16]. The multispecimen study documented 272 that adding multiple rather than a single specimen to NP/nasal swab approximately doubled 273 RSV detection [12, 15]. Adjustment of adult RSV disease incidence estimates for diagnostic 274 testing sensitivity has been incorporated in multiple recent studies, including meta-analyses of 275 RSV disease rates in high-income countries [8] and the United States [18] as well as in recent 276 US CDC incidence analyses [26]. Notably, the latter two studies only accounted for the 277 percentage increase in detection rate with adding one more specimen (1.3 to 1.5-fold) whereas

the most recent global study, similar to ours, included adjustment factors of ~2 to account for the additional infections that would be identified through the synergistic effect of adding multiple additional specimens (i.e., saliva, sputum, and paired serology).

281

In our study, more than one third of patients aged 65 years or older with RSV-related CAP developed a cardiovascular event. Our results confirm previous observations of a high risk for cardiovascular events following RSV infections in older adults consistent with more extensively studied respiratory infections such as influenza and SARS-CoV-2 [27-29]. Time-series modelling has also documented a linkage between RSV and acute cardiac events [30]. A recent time-series study of hospitalization incidence in Germany found that 2–3% of cardiovascular

hospitalizations could be attributed to RSV infection [21].

289

Our study had several strengths. Broad screening criteria allowed for near complete case capture and collection of minimal data on non-enrolled patients with study-qualifying CAP allowed for accurate incidence estimations. Among enrolled patients, testing rates were high (93%). A further strength of our study is the precise definition and consistent use of the catchment area population based on residential zip codes, which allowed for accurate estimations of RSV-related CAP incidence among adults.

296

The study also has several limitations. First, the estimation of RSV-related ARI hospitalization incidence relies on the proportions of CAP among RSV-related ARI hospitalizations among adults aged  $\geq$ 40 years in the multispecimen study conducted in North America and may not be fully applicable to the German population [12]. Available literature suggests that the estimate that CAP is 28% of RSV-related ARI hospitalization [12] is conservative, as other publications have reported percentages as low as 14% [4], which would have resulted in higher incidence estimates. Second, diagnostic testing sensitivity adjustment in the current study was based on

304 results from a North American population 40 years and older. However, a recent systematic 305 literature found multiple studies documenting the reduced sensitivity of single NP/nasal swab 306 PCR testing and similar results were seen among different adult age groups and geographical 307 settings [16]. Further, minimal differences by age in the underascertainment of single specimen 308 were seen within the study itself and this is the largest study of its kind with 3,669 participants 309 tested and 2 countries represented (US and Canada) [12]. Third, we assumed that CAP 310 participants who received RSV testing would have the same RSV detection rate as those who 311 were not tested. Untested persons, especially those that could not be enrolled in the study 312 because of lack of informed consent may have had a different detection rate since they tended 313 to be slightly older but were less likely to be at high-risk. However, the RSV detection rates were 314 observed to be similar across risk status (3.3% for low-risk, 3.5% for at-risk and 3.9% for high-315 risk). Fourth, incidence rates were calculated for Jena only and the city's catchment population 316 is somewhat younger than the national average, potentially leading to lower RSV incidence than 317 would have been see in Germany as a whole as RSV-related hospitalization incidence is known 318 to increase with age [18,19]. Lastly, the surveillance period in the CAP incidence study 319 coincided with the COVID-19 pandemic and its immediate aftermath with larger fluctuations of 320 incidence, which may not reflect future RSV incidence.

321

322 While RSV burden estimates relying on standard-of care testing or hospital discharge codes 323 result in a large underestimation of the RSV-related ARI incidence, our study based on 324 prospective, active population-based surveillance and adjustment for underascertainment 325 provides more accurate and complete estimates. The high risk of case-fatality and 326 cardiovascular events after RSV-related CAP confirms similar observations from other studies 327 with larger sample size. The study results underscore the substantial burden of RSV among 328 adults in Germany. This evidence is essential for the evaluation and implementation of novel 329 antiviral agents for treatment and vaccines for prevention of infections due to RSV.

## 330 Acknowledgements

- 331 Steffi Kolanos led the study nurse team and were responsible for the local logistics of the study.
- 332 Susana Cubillos de Schmeer took over the management of the study team in the final phase of
- the study. The study nurses Stephanie Beier, Jana Schmidt, Janine Wittig and Claudia Merbold
- an enrolled the patients.
- 335

### **Data availability**

- 337 All data generated or analyzed during this study are included in this published article and
- 338 supplementary materials.

339

#### 340 Ethical statement

- 341 All study participants or legal representatives were informed about the study and consented to
- 342 the participation. The study was approved by the Ethics Committee of the Jena University
- Hospital on 19 November 2020 (reg.no. "2020-1947- material") and also by the
- Landesärztekammer Thüringen (local ethics committee) on 22 December 2020.

345

#### 346 Authors' contributions

- 347 C.L., E.B., B.D.G., C.T., and M.P. contributed to conception and/or study design. C.L., E.B.,
- 348 S.H., L.W., Q. L., C.T., and M.P. were involved in acquisition of data, analysis and interpretation
- 349 of data. C.L., E.B., S.H., J.A., L.W., C.S., L.J.B., C.V.E., Q.L., J.S., J.V., S.U., B.D.G., C.T., and
- 350 M.P. participated in drafting or revision of the submitted article.

## 351 References

Feldman C, Shaddock E. Epidemiology of lower respiratory tract infections in adults. Expert Rev
 Respir Med. 2019;13(1):63-77.
 Collaborators GBDLRI. Estimates of the global, regional, and national morbidity, mortality, and

aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the
 Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-210.

357 3. Hyams C, Begier E, Garcia Gonzalez M, Southern J, Campling J, Gray S, et al. Incidence of acute 358 lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, 359 estimated using both a prospective and retrospective methodology. BMJ Open. 2022;12(6):e057464.

3604.Aronen M, Viikari L, Kohonen I, Vuorinen T, Hameenaho M, Wuorela M, et al. Respiratory tract361virus infections in the elderly with pneumonia. BMC Geriatr. 2019;19(1):111.

Theilacker C, Sprenger R, Leverkus F, Walker J, Hackl D, von Eiff C, et al. Population-based
 incidence and mortality of community-acquired pneumonia in Germany. PLoS One.
 2021;16(6):e0253118.

3656.Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an366assessment of disease burden. J Infect Dis. 1999;179(1):25-30.

367 7. van Asten L, van den Wijngaard C, van Pelt W, van de Kassteele J, Meijer A, van der Hoek W, et
368 al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial
369 virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis. 2012;206(5):628-39.

370
8. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for Case Under371
Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a
372
Systematic Review and Modelling Study. Infect Dis Ther. 2023;12(4):1137-49.

373 9. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired 374 Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415-27.

Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med.
 2007;28(2):171-81.

377 11. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev.
378 2000;13(3):371-84.

379 12. Aliabadi N, Ramirez J, McGeer A, Liu Q, Carrico R, Mubareka S, et al., editors. Detection of 380 Respiratory Syncytial Virus (RSV) using nasopharyngeal specimens (NPS) alone significantly

Respiratory Syncytial Virus (RSV) using hasopharyngeal specimens (NPS) alone significantly

underestimates disease incidence in adults hospitalized with acute respiratory infections (ARI): an
 updated, pooled analysis from North America. Poster presentation. 8th Global ReSVINET Conference on

383 Novel RSV Preventive and Therapeutic Interventions; 2024 February 13-16, 2024 Mumbai, India.

13. Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, et al. Incidence of

Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infect Dis Ther.
 2023;12(6):1487-504.

Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low Levels of RSV Testing Among
Adults Hospitalized for Lower Respiratory Tract Infection in the United States. Infect Dis Ther.
2023;12(2):677-85.

Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al. Diagnosis of Respiratory
 Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to
 Nasopharyngeal Swab RT-PCR. Infect Dis Ther. 2023;12(6):1593-603.

393 16. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment
 394 of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic
 395 Literature Review and Meta-analysis. J Infect Dis. 2023;228(2):173-84.

396 17. Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. Infect Disord Drug
 397 Targets. 2012;12(2):98-102.

398 18. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of Medically Attended

- 399 RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infect Dis.
- 400 2022;9(7):ofac300.
- 401 19. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code 402 data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630-7.
- 403 20. Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C, Nuttens C, et al. Estimated
- 404 Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 405 2016-2019. Infect Dis Ther. 2024;13(3):463-80.
- 406 21. Polkowska-Kramek A, Begier E, Bruyndonckx R, Liang C, Beese C, Brestrich G, et al. Estimated
   407 Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among
- 408 Adults in Germany Between 2015 and 2019. Infect Dis Ther. 2024.
- 409 22. Ankert J, Hagel S, Schwarz C, Pan K, Wang L, von Eiff C, et al. Streptococcus pneumoniae re-
- 410 emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-
- 411 2, in Germany, 2021. ERJ Open Res. 2023;9(3).
- 412 23. CDC. Risk Factors for Pneumococcal Disease [Available from:
- 413 <u>https://www.cdc.gov/pneumococcal/about/risk-</u>

414transmission.html#:~:text=Conditions%20and%20other%20factors%20that,kidney%2C%20liver%2C%20415or%20lung%20disease.

416 24. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial

417 Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices

418 - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801.

419 25. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic Literature Review

420 of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-

- 421 Income Countries. Open Forum Infect Dis. 2023;10(11):ofad513.
- 422 26. Havers FP, Whitaker M, Pham H, Anglin O, Milucky J, Patel K, et al. 2209. RSV-associated
   423 Hospitalizations in Adults Aged ≥18 Years and the Impact of the COVID-19 Pandemic in the United

424 States, October 2018 – February 2022. Open Forum Infect Dis. 2022;9(Suppl 2): ofac492.1828.

- 425 27. Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al. Acute Cardiac Events
  426 in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Intern Med. 2024.
- 427 28. Ubamadu E BE, Gessner BD et al. Respiratory syncytial virus sequelae among adults in high-

428 income countries. A systematic literature review and meta-analysis. Infect Dis Ther. May 2024 In Press.

- 429 29. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With
- 430 Cardiovascular Disease in Adults. J Am Coll Cardiol. 2018;71(14):1574-83.
- 431 30. Bruyndonckx R, Polkowska-Kramek A, Liang C, Nuttens C, Tran TMP, Gessner BD, et al.
- 432 Estimation of Symptomatic Respiratory Syncytial Virus Infection Incidence in Adults in Multiple
- 433 Countries: A Time-Series Model-Based Analysis Protocol. Infect Dis Ther. 2024;13(4):953-63.
- 434

# Tables

	NP/Nasal S	wab Tested	NP/Nasal Swa	NP/Nasal Swab Untested***		
	Ν	%	Ν	%	P-Value	
Overall	293	100	741	100		
Age group						
18-59 years	38	13	73	9.9	0.145	
≥60 years	255	87	668	90.1	0.145	
18-64 years	66	22.5	117	15.8	0.010	
≥65 years	227	77.5	624	84.2	0.010	
Sex						
Female	125	42.7	309	41.7	0.778	
Male	168	57.3	432	58.3		
Study period*						
Year 1	135	46.1	341	46	0.987	
Year 2	158	53.9	400	54	0.987	
Overall study period	293	100	741	100		
Risk status**						
Low-risk	18	6.1	62	8.4	0.228	
At-risk	104	35.5	391	52.8	<0.001	
High-risk	171	58.4	287	38.7	<0.001	

Table 1. Characteristics of adults hospitalized at Jena University Hospital with radiologically-	
confirmed CAP patients by RSV testing status	

Abbreviations: CAP=community-acquired pneumonia; CDC = centers for disease. NP/nasal swab=nasopharyngeal (NP)/nasal swab

\* Year 1: 01Jul2021 - 30Jun2022; Year 2: 01Jul2022 - 30Jun2023

\*\* The risk status was classified using CDC definitions for pneumococcal disease [23]

\*\*\* include enrolled and non-enrolled patients

Age group (Years)	CAP incidence rate (per 100, 000) <sup>1</sup>	RSV positive proportion based on	Percentage Increase in	RSV-related CAP incidence rate per 100,000 (95% confidence interval) <sup>3</sup>		Proportion of CAP in RSV- related ARI	RSV-related ARI incidence rate per 100,000 (95% confidence interval) <sup>6</sup>	
			NP/nasal swab <sup>1</sup>	RSV – detection <sup>2</sup>	Unadjusted	Adjusted <sup>4</sup>	hospitalization <sup>5</sup>	Unadjusted
Year 1: 0	1Jul2021 – 30Jun2022							
≥18	451.0 (410.0, 494.5)	2.3%	112%	10.4 (5.1,18.9)	22.0 (13.8, 33.3)	28.0%	37.0 (26.1, 51.0)	78.5 (62.1, 97.9)
18-59	87.7 (70.6, 108.4)	2.3%	148%	2.0 (0.2,7.2)	5.0 (1.6, 11.7)	25.4%	7.9 (3.4, 15.6)	19.7 (12.0, 30.5)
≥60	1188.0 (1121.8, 1257.1)	2.3%	101%	27.3 (18.0,39.6)	54.9 (41.3, 71.5)	28.9%	94.5 (76.4, 115.6)	190.0 (163.9, 219.0)
18-64	119.4 (98.6, 142.4)	1.7%	141%	2.0 (0.2, 7.2)	4.9 (1.6, 11.5)	22.6%	9.0 (4.1, 17.1)	21.6 (13.5, 32.8)
≥65 <b>Year 2: 0</b>	1384.5 (1312.5, 1458.3) 1Jul2022 – 30Jun2023	2.7%	95%	37.4 (26.4, 51.5)	72.9 (57.1, 91.7)	31.8%	117.6 (97.3, 140.9)	229.2 (200.5, 260.9) ≧
≥18	528.7 (485.0, 575.9)	5.5%	112%	29.1 (19.5, 41.8)	61.6 (47.2, 79.0)	28.0%	103.9 (84.9, 125.9)	يج. 220.2 (192.1, 251.3)
18-59	69.3 (53.7, 87.3)	2.6%	148%	1.8 (0.2, 6.9)	4.5 (1.4, 11.0)	25.4%	7.1 (2.9, 14.6)	17.6 (10.4, 28.0)
≥60	1460.6 (1387.5, 1537.3)	6.1%	101%	89.1 (71.6, 109.6)	179.1 (153.8, 207.3)	28.9%	308.3 (274.8, 344.7)	م 619.7 (571.9, 670.5)
18-64	115.6 (95.9, 139.1)	4.2%	141%	4.9 (1.6, 11.5)	11.7 (6.0, 20.6)	22.6%	21.5 (13.4, 32.7)	51.8 (38.7, 68.0
≥65	1691.7 (1613.0, 1773.9)	6.0%	95%	101.5 (82.7, 123.3)	197.9 (171.3, 227.5)	31.8%	319.2 (285.1, 356.2)	622.4 (574.5, 673.3 g
Overall s	tudy period: 01Jul2021 –	30Jun2023						
≥18	489.8 (460.4, 520.6)	3.7%	112%	18.1 (10.7, 28.6)	38.4 (27.2, 52.6)	28.0%	64.7 (49.9, 82.5)	137.2 (115.2, 162.2)
18-59	78.5 (64.6, 94.5)	2.4%	148%	1.9 (0.2, 7.1)	4.7 (1.5, 11.2)	25.4%	7.4 (3.1, 15.0)	18.4 (11.0, 28.9 <u>£</u>
≥60	1324.3 (1241.3, 1411.3)	4.1%	101%	54.3 (40.8, 70.8)	109.1 (89.6, 131.6)	28.9%	187.9 (162.0, 216.8)	ਰੂ 377.6 (340.5, 417.7
18-64	117.5 (101.1, 135.8)	2.5%	141%	2.9 (0.6, 8.6)	7.1 (2.9, 14.6)	22.6%	13.0 (6.9, 22.2) 203.1 (176.1,	31.3 (21.3, 44.4
≥65	1538.1 (1437.9, 1643.2)	4.2%	95%	64.6 (49.8, 82.4)	126.0 (105.0, 150.0)	31.8%	233.0)	396.1 (358.0, 437.1 <sup>∰</sup> .

### Table 2 Unadjusted and adjusted incidence rates of RSV-related CAP and ARI hospitalizations in Thuringia/Germany 2021–2023

Abbreviations: CAP=community-acquired pneumonia; ARI= acute respiratory infection; RSV=respiratory syncytial virus; NP/nasal swab=nasopharyngeal (NP)/nasal swab1. Obtained from the active, population-based surveillance study. CAP incidence estimates are taking into account Jena patients only; however, all three sites contributed to the RSV positive proportion

2. Percentage increase with additional specimen type results beyond NP/nasal swab, obtained from the multi-specimen study

3. Assumes the RSV positive proportion is the same among CAP patients tested and untested.

4. Adjusted for the underascertainment of RSV detection using the percentage increase with additional specimen type results beyond NP/nasal swab, obtained from the multi-specimen study\*

5. Proportions of CAP among RSV-related ARI hospitalizations were obtained from the multi-specimen study

6. Calculated by dividing RSV-related CAP incidence by the proportion of CAP in RSV-related ARI hospitalizations

\* Aliabadi N, et al Detection of Respiratory Syncytial Virus (RSV) using nasopharyngeal specimens (NPS) alone significantly underestimates disease incidence in adults hospitalized with acute respiratory infections (ARI): an updated, pooled analysis from North America. 8th Global ReSVINET Conference. Mumbai, India2024.